COPD吸入性糖皮质激素与肺功能下降的药物基因组学研究
该研究在Lung Health Study-2的1116例COPD患者中开展药物基因组学全基因组关联研究,分析基因型与ICS治疗对3年FEV1变化斜率的交互作用,发现染色体7上SNP rs111720447的交互效应在另一组199例COPD患者中重复验证,提示遗传因素可能影响COPD患者对ICS的肺功能反应。
要点
- SNP rs111720447与ICS治疗对FEV1年下降率存在交互作用,且在复制队列中同向验证。
- 在LHS-2中,携带C等位基因者使用ICS时FEV1年下降β为56.36 mL·year-1(95%CI 29.96-82.76)。
- 同一C等位基因在安慰剂组FEV1年下降β为-27.57 mL·year-1(95%CI -53.27至-1.87),方向相反且关联较弱。
核心结论
- 研究发现了与COPD患者ICS相关FEV1变化有关的遗传因素,可能为COPD激素反应性的潜在生物学提供新见解。
研究设计与样本
- 在Lung Health Study (LHS)-2中,1116例COPD患者随机接受ICS曲安奈德(n=559)或安慰剂(n=557),每6个月进行肺功能检查持续3年。
- 在802例有基因型的LHS-2参与者中,对3年FEV1变化斜率进行基因型-by-ICS治疗效应的药物基因组学全基因组关联研究。
- 在199例随机接受ICS氟替卡松或安慰剂的COPD患者中进行重复验证。
主要发现
- 共5个位点显示基因型-by-ICS交互作用p<5×10-6。
- 染色体7上SNP rs111720447被重复验证(发现p=4.8×10-6,复制p=5.9×10-5),交互效应方向一致。
- ENCODE数据显示,在地塞米松处理的A549肺泡细胞系中,糖皮质激素受体结合位点位于SNP rs111720447附近。
- LHS-2分层分析中,SNP rs111720447基因型与使用ICS患者的FEV1下降率显著相关(C等位基因β 56.36 mL·year-1,95%CI 29.96-82.76 mL·year-1)。
- 在安慰剂组中,同一基因型与FEV1下降率关联较弱且方向相反(C等位基因β -27.57 mL·year-1,95%CI -53.27至-1.87 mL·year-1)。
临床怎么用
- 该发现提示未来或可通过基因检测识别COPD患者中ICS对肺功能下降影响不同的亚群,但当前尚未形成临床推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inhaled corticosteroids (ICS) are widely prescribed for patients with chronic obstructive pulmonary disease (COPD), yet have variable outcomes and adverse reactions, which may be genetically determined. The primary aim of the study was to identify the genetic determinants for forced expiratory volume in 1 s (FEV1) changes related to ICS therapy.In the Lung Health Study (LHS)-2, 1116 COPD patients were randomised to the ICS triamcinolone acetonide (n=559) or placebo (n=557) with spirometry performed every 6 months for 3 years. We performed a pharmacogenomic genome-wide association study for the genotype-by-ICS treatment effect on 3 years of FEV1 changes (estimated as slope) in 802 genotyped LHS-2 participants. Replication was performed in 199 COPD patients randomised to the ICS, fluticasone or placebo.A total of five loci showed genotype-by-ICS interaction at p<5×10-6; of these, single nucleotide polymorphism (SNP) rs111720447 on chromosome 7 was replicated (discovery p=4.8×10-6, replication p=5.9×10-5) with the same direction of interaction effect. ENCODE (Encyclopedia of DNA Elements) data revealed that in glucocorticoid-treated (dexamethasone) A549 alveolar cell line, glucocorticoid receptor binding sites were located near SNP rs111720447. In stratified analyses of LHS-2, genotype at SNP rs111720447 was significantly associated with rate of FEV1 decline in patients taking ICS (C allele β 56.36 mL·year-1, 95% CI 29.96-82.76 mL·year-1) and in patients who were assigned to placebo, although the relationship was weaker and in the opposite direction to that in the ICS group (C allele β -27.57 mL·year-1, 95% CI -53.27- -1.87 mL·year-1).The study uncovered genetic factors associated with FEV1 changes related to ICS in COPD patients, which may provide new insight on the potential biology of steroid responsiveness in COPD.
引用
- Obeidat M, Faiz A, Li X, et al. The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD. Eur Respir J. 2019. PMID: 31537701. doi:10.1183/13993003.00521-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。